December 19 2010 | Evado has entered a partnership with Taiwan’s clinical research organization, Fuga Biotechnology which will have exclusive distribution rights in Taiwan. Evado said it would develop a Chinese version of the Evado clinical trials software system with Fuga in 2011. Evado chief executive officer Jennie Anderson said that the agreement extended to the localization of the software for the Taiwanese regulatory environment. “This is a great opportunity to work with a world class contract research organization that is extremely well respected in Taiwan,” Ms Anderson said in a press release. Evado